Working Instruction SWIFT: **Worksheet (Pre-)Screening**

***"*Early factor XIII replacement in postpartum hemorrhage: multi-center, randomized, controlled, investigator-initiated trial".** Sponsor: Prof. Dr. med. Christian Haslinger

Patient ID:	**Date Informed Consent signed:**
	☐ **short consent** ☐ **full consent version**

Inclusion criteria

	YES	**NO**
1. Planned vaginal delivery	☐	☐
2. Singleton vital pregnancy	☐	☐
3. Gestational age at delivery ≥30+0 weeks	☐	☐
4. Maternal weight at admission for delivery <100 kg	☐	☐
5. Maternal age ≥18 years	☐	☐
If one inclusion criterion is ticked **NO** – the patient is **NOT ALLOWED** to be enrolled in the study!		

Exclusion criteria

	YES	**NO**
1. Antithrombotic therapy in pregnancy (therapeutic dosage) until admission for delivery (LMWH, UFH), (Note: regular inpatient antithrombotic prophylaxis is no exclusion criterion)	☐	☐
2. Diagnosis of preeclampsia (2021 ISSHP classification), eclampsia or HELLP syndrome	☐	☐
3. History of deep vein thrombosis or pulmonary embolism	☐	☐
4. Diagnosis of bleeding disorder or thrombophilia	☐	☐
5. Known thrombocytopenia during second half of pregnancy with thrombocytes < 100 G/L	☐	☐
6. Anemia during second half of pregnancy with Hb<80 g/L	☐	☐
7. Known sickle cell disease	☐	☐
8. malignant tumor(s)	☐	☐
9. participation in another study with investigational drug within the 30 days preceding and during the present study	☐	☐
10. inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant	☐	☐
11. known or suspected non-compliance, drug or alcohol abuse	☐	☐
If one exclusion criterion is ticked **YES** – the patient is **NOT ALLOWED** to be enrolled in the intervention!		

INVESTIGATOR'S SIGNATURE

_____

Name:

_____ _____

Date Signature